Biotech Acquisition Company Class A Ordinary Shares
BIOT
BIOT was delisted on the 2nd of February, 2023.
76 hedge funds and large institutions have $211M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 8 closing their positions.
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
44% more capital invested
Capital invested by funds: $146M → $211M (+$64.9M)
31% more funds holding
Funds holding: 58 → 76 (+18)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$11.3M |
| 2 |
CM
Cohanzick Management
Pleasantville,
New York
|
+$7.84M |
| 3 |
RA
RiverPark Advisors
New York
|
+$7.84M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$5.9M |
| 5 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$5.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRCM
Sage Rock Capital Management
New York
|
-$5.59M |
| 2 |
ACM
Atalaya Capital Management
New York
|
-$5.4M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.92M |
| 4 |
CC
Centiva Capital
New York
|
-$2.42M |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$498K |
BIOT Hedge Fund Activity: Q4 2021 in Review
76 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q4 2021, worth a combined $211M — up 44% from $146M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new BIOT positions and 8 closed out — a net gain of 18 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was Aristeia Capital, opening a new position worth an estimated $11.3M. The largest seller was Sage Rock Capital Management, exiting entirely with an estimated $5.59M sold.
- 76 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q4 2021, up from 58 in Q3 2021.
- Funds reported $211M of Biotech Acquisition Company Class A Ordinary Shares stock for Q4 2021, up 44% quarter-over-quarter.
- 26 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q4 2021 and 8 closed out, a net change of +18 holders.
- The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q4 2021 was Aristeia Capital, an estimated $11.3M added.
- The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q4 2021 was Sage Rock Capital Management, an estimated $5.59M sold.
Based on aggregated 13F filings for Q4 2021.